NCT03856216 2026-04-15
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
11 trialsNCT00534469 2025-12-02
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
Phase 2 Completed
NCT02100891 2025-03-19
STIR
Medical College of Wisconsin
Phase 2 Terminated
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT00469014 2021-01-26
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00506129 2020-12-29
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00612716 2020-12-09
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00303719 2020-05-12
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00505895 2014-10-17
FM 140 vs FM100 Study in Patients With Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00593645 2014-09-12
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
Washington University School of Medicine
Phase 2 Terminated
NCT00499889 2012-04-23
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
M.D. Anderson Cancer Center
Phase 2 Terminated